Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 65

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 65
---
) spend
reductions related to facilities, marketing and staff. STAAR also announced that it was withdrawing the financial guidance it previously provided on February 11, 2025, in light of economic uncertainty and tariff policies that made it more
challenging to forecast potential results. On May 8, 2025, the trading price of STAAR common stock closed at $19.53 per share.

-40-

On May 25, 2025, STAAR announced that the Board authorized a share repurchase program
for the repurchase of up to $30 million of STAAR common stock.

On May 30, 2025, representatives of Morgan Stanley,
Alcon’s financial advisor, contacted representatives of Citi to express Alcon’s renewed interest in a potential transaction with STAAR. Representatives of Citi informed Mr. Farrell of the conversation.

At STAAR’s June 18, 2025 Board meeting, which was held on the same day as STAAR’s 2025 annual meeting of stockholders,
Mr. Farrell discussed with the Board, among other things, his introductory meeting with Mr. Endicott in April and Alcon’s apparent renewed interest in a business combination. The Board authorized Mr. Farrell to meet with
Mr. Endicott to assess Alcon’s interest in a potential transaction. At the meeting, the Board also discussed STAAR’s business plan and standalone strategy, including opportunities and risks associated therewith. During the meeting,
the Board reviewed STAAR’s performance for the first quarter 2025, preliminary financial expectations for the second quarter 2025, and STAAR’s latest estimates for full year 2025. Among other things, the Board discussed risks and
opportunities facing STAAR’s business in China, including the potential for increased competition, uncertainty regarding the recovery in refractive procedure volumes, and possible pricing controls.

Also on June 18, 2025, Mr. Endicott contacted Mr. Farrell to indicate Alcon was interested in
re-engaging in discussions about a potential transaction and requested an in-person meeting the following week.

On June 25, 2025, STAAR announced the formation of a new committee of its Board, the Capital Stewardship Committee, to help guide
STAAR’s financial strategies, including the responsible allocation, management and oversight of capital, and also announced the appointment of Deborah Andrews as STAAR’s Chief Financial Officer, following her service as interim Chief
Financial Officer since March 2025.

On June